Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelLBxHealthLSE:CLBX Cyclically Adjusted PS Ratio is 1.28 as of Jul. 29, 2026, which is 89% below its 10-year median of 12.15. The stock has 5 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, CelLBxHealth ranks better than 51.85% on this metric.
The historical rank and industry rank for CelLBxHealth's Cyclically Adjusted PS Ratio or its related term are showing as below:
LSE:CLBX'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.9 Med: 12.15 Max: 144.27
Current: 1.8
During the past 13 years, CelLBxHealth's highest Cyclically Adjusted PS Ratio was 144.27. The lowest was 0.90. And the median was 12.15.
LSE:CLBX's Cyclically Adjusted PS Ratio is ranked better than 51.85% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.88
vs LSE:CLBX: 1.80
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
CelLBxHealth's adjusted revenue per share data of for the fiscal year that ended in Dec25 was £0.004. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is £0.01 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
CelLBxHealth (LSE:CLBX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
CelLBxHealth Cyclically Adjusted PS Ratio Related Terms
CelLBxHealth Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for CelLBxHealth's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CLBX vs TMO, DHR, IDXX: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, CelLBxHealth's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's Cyclically Adjusted PS Ratio falls into.
CelLBxHealth Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
CelLBxHealth's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.28 mean?
CelLBxHealth (LSE:CLBX) has a Cyclically Adjusted PS Ratio of 1.28 as of Jul. 29, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on CelLBxHealth and its competitors. This is 89% below median its historical median of 12.15. Over the past decade, CelLBxHealth's Cyclically Adjusted PS Ratio has ranged from 0.90 to 144.27. According to the industry distribution chart, CelLBxHealth ranks #65 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 48.1%.
Is CelLBxHealth's Cyclically Adjusted PS Ratio too high?
CelLBxHealth's current Cyclically Adjusted PS Ratio of 1.28 is 89% below median its 10-year median of 12.15. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 144.27. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 1.88. CelLBxHealth's value of 1.28 is 31.9% below this industry median. Based on the distribution chart, CelLBxHealth ranks #65 out of 135 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does CelLBxHealth's Cyclically Adjusted PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #65 out of 135 companies for Cyclically Adjusted PS Ratio. This puts CelLBxHealth in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.88. CelLBxHealth's value of 1.28 is 31.9% below this benchmark. Historically, CelLBxHealth's own Cyclically Adjusted PS Ratio has ranged from 0.90 to 144.27 over the past decade. While the company's 10-year median is 12.15 vs. the industry median of 1.88, CelLBxHealth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 1.88, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CelLBxHealth's current Cyclically Adjusted PS Ratio of 1.28 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on CelLBxHealth and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CelLBxHealth's current Cyclically Adjusted PS Ratio is 1.28, which is 89% below median its own 10-year median of 12.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (LSE:CLBX) has a current Cyclically Adjusted PS Ratio of 1.28. The current Cyclically Adjusted PS Ratio is 1.28, which is 89% below median its 10-year median of 12.15 and 31.9% below the Medical Diagnostics & Research industry median of 1.88. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For CelLBxHealth (LSE:CLBX), the current Cyclically Adjusted PS Ratio is 1.28 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CLBX has been successfully added to your 
